Daniel A.
- Country
- Sweden
- Department
- Center for Metabolism and Endocrinology, Department of Medicine, Hälsovägen 1
Research Overview
- Evaluation of ISIS 678354 Sodium Salt in Patients with Severe Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
- Randomized Double-Blind Trial of Sodium Hypochlorite and Polyhexamethylene Biguanide for Diabetic Foot Ulcer Healing Efficacy
- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG)
Data & Insights
Has run more than one trial at 62 of 178 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in the management of severe hypertriglyceridemia (SHTG), focusing on innovative therapeutic approaches for patients with elevated triglyceride levels.
- Lipid metabolism disorders
- Triglyceride regulation
- Cardiovascular risk management
The investigator explores novel treatment options for patients with challenging metabolic conditions affecting lipid metabolism.
Therapeutic Innovation
Expertise in evaluating new therapeutic compounds for metabolic disorders, with particular attention to safety and efficacy in treating severe lipid abnormalities.
- Novel therapeutic agents
- Treatment optimization
- Patient response assessment
The research focuses on advancing treatment options for patients with severe metabolic conditions.
Clinical Assessment
Specializes in evaluating treatment outcomes and monitoring therapeutic responses in patients with severe metabolic disorders.
- Biomarker analysis
- Treatment effectiveness
- Patient safety monitoring
Focuses on comprehensive assessment of therapeutic interventions in metabolic disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.